Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. - Wikidata - awgldk - TriplyDB

Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction.

Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction.

http://www.wikidata.org/entity/Q35506589

about

A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight The risks of selective serotonin reuptake inhibitor use in infertile women: a review of the impact on fertility, pregnancy, neonatal health and beyond Prenatal antidepressant exposure: clinical and preclinical findings.Antidepressants may mitigate the effects of prenatal maternal anxiety on infant auditory sensory gating.Antidepressant use in pregnant and postpartum women Agreement between self-report and prescription data in medical records for pregnant women.Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis.Impact of physician counseling and perception of teratogenic risks: a survey of 96 nonpregnant women with anxiety Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Disturbed sleep, a novel risk factor for preterm birth?Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth.The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring Migraine therapy during pregnancy and lactation.Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making.The comparative safety of buprenorphine versus methadone in pregnancy-what about confounding?Risks versus benefits of medication use during pregnancy: what do women perceive?Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy.Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series.

P2860

Q24623163-82207812-840B-4DAE-8D8D-918FB4D3A549 Q27010327-0643360A-8C32-40D1-9540-87D82B42C2EA Q30415540-0765E962-9C12-412B-A113-49C3426CD353 Q30453943-FB03D1F3-5B5A-4224-8489-4839520AC736 Q34068023-6FD59C1D-8B22-4415-BC18-C1FB572EF5A4 Q34130041-A0D1BBF9-E4B0-4242-96B4-1DE33E77A81A Q34178991-22CDA8B7-0A4B-40F0-99CB-0BB79EA068A2 Q35132422-27BA02F9-1AD5-4610-8995-16838963AB23 Q35252134-65A0E3B5-2112-469B-B3FD-FE6D249BD181 Q35608913-96EBD805-08E3-4D04-B3F7-D9CC07E7F636 Q35667928-7D9508FD-8ABD-4F3D-8BC5-02F0464E36A4 Q36152982-2F14740F-463E-474A-91CC-B85B66C4D574 Q36860205-20068A15-65E8-4824-9A6B-809D6EA91A71 Q37775960-591A51DA-31C9-4058-A7DE-3BD2E20AC017 Q37943435-9AA7A1A1-F6E6-4100-AA91-C680481CE755 Q38661049-E56CE481-2370-4F97-8106-9F777018BCF3 Q38811512-055F1233-8474-4BBA-AEEF-5A5E782C2063 Q40386069-AEDF8491-64F6-434B-B4BB-3988F5C453F3 Q47128647-1D3AD524-B67B-4D78-AEE5-62947D06A96E Q48896306-333758D6-F8AD-4E53-9FD1-65EBC4CA8AB6 Q50902951-29084D31-E052-4E47-BF8A-EA7AC9286DE8

P2860

Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction.

http://www.wikidata.org/entity/Q35506589

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Antidepressant use during preg ...... and fetal growth restriction.

@ast

Antidepressant use during preg ...... and fetal growth restriction.

@en

type

label

Antidepressant use during preg ...... and fetal growth restriction.

@ast

Antidepressant use during preg ...... and fetal growth restriction.

@en

prefLabel

Antidepressant use during preg ...... and fetal growth restriction.

@ast

Antidepressant use during preg ...... and fetal growth restriction.

@en

P1433

Q35506589-D6879C5A-28CF-4A04-8384-6183ED80BF83

P1476

Q35506589-1F4E37E6-A25E-46C1-A60B-F4AF579A188A

P2093

Q35506589-2EB0F2C1-1646-41F9-9E91-2F765EE78861

Q35506589-6A28A989-48F5-488B-98B1-201A1BA77F53

Q35506589-90D1D3B1-350D-40CE-96C1-7B0A4ED65219

Q35506589-D10F742F-96C3-4BE9-845B-CA98A1361D2A

Q35506589-EFD291A4-23AC-4B83-B5A4-D8D79651F6DA

P2860

Q35506589-04A5437D-1831-4FDE-9250-0CAD61845725

Q35506589-073CD18E-D39C-4B46-A5E5-49867BC0A783

Q35506589-14DE7A22-F65C-4F2B-84C8-C11F27F32B7E

Q35506589-15BBCA4F-682C-44DE-AA97-A9EE532A52D4

Q35506589-1A837064-BA7B-4FE0-A2F8-6702C4D892CA

Q35506589-2B10B749-736B-4CA1-A866-2B8EB91219F2

Q35506589-36C92A59-A8B5-48B1-A3CA-B656DD9365BD

Q35506589-4495AF24-AF93-43A9-A32C-37E8A2E62719

Q35506589-5413343D-5530-4EF7-ABBE-9144BCEDF741

Q35506589-6D03B76F-4713-4BCE-BFE1-9FCCCEA483CC

P304

Q35506589-A40CBAB1-E107-43A2-8C40-CFDE835B1267

P31

Q35506589-F02F7EA9-3A6E-4A92-9950-625B2665C643

P356

Q35506589-3C56E57E-C2F6-4C08-A0CF-25A8197D9C2F

P407

Q35506589-E51D51FD-F22E-4C42-91B8-E1CFBC699E78

P433

Q35506589-39A6C164-09B7-4574-85EC-A641AFD0B8D4

P478

Q35506589-398747CD-BE97-4249-A901-3865799A399F

P50

Q35506589-57C8DA95-F15D-4203-BC82-1F13177BA1BE

P577

Q35506589-BBA6BB2C-584B-4058-BC1F-21A04B35AA7A

P698

Q35506589-63880023-6ADE-406B-A832-E0366175346B

P932

Q35506589-549F1E23-C48E-4EDD-8558-BFD89205A5C1

P356

JCP.0B013E3181BF344C

P1433

Journal of Clinical Psychopharmacology

P1476

Antidepressant use during preg ...... and fetal growth restriction.

@en

P2093

Allen A Mitchell

http://www.w3.org/2001/XMLSchema#string

Christina D Chambers

http://www.w3.org/2001/XMLSchema#string

Martha M Werler

http://www.w3.org/2001/XMLSchema#string

Sengwee Toh

http://www.w3.org/2001/XMLSchema#string

Sonia Hernández-Díaz

http://www.w3.org/2001/XMLSchema#string

P2860

A nearly continuous measure of birth weight for gestational age using a United States national reference

Neurodevelopment of children exposed in utero to antidepressant drugs

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

The long-term costs of preterm birth and low birth weight: results of a systematic review.

Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.

Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

Risks associated with selective serotonin reuptake inhibitors in pregnancy.

First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.

The safety of antidepressant drugs during pregnancy.

Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study.

P304

555-560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JCP.0B013E3181BF344C

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19910720

http://www.w3.org/2001/XMLSchema#string

P932

3206605

http://www.w3.org/2001/XMLSchema#string